Abstract: Calprotectin is an abundant neutrophil protein found in both plasma and stool that is markedly elevated in infectious and inflammatory conditions, including inflammatory bowel disease (IBD). We conducted a systematic review of the published literature regarding fecal calprotectin to evaluate its potential as a noninvasive marker of neutrophilic intestinal inflammation. Reference ranges for fecal calprotectin have been established in healthy adults and children, and elevated concentrations of fecal calprotectin have been demonstrated in numerous studies of patients with IBD. Fecal calprotectin correlates well with histological inflammation as detected by colonoscopy with biopsies and has been shown successfully to predict relapses and detect pouchitis in patients with IBD. Fecal calprotectin has been shown to consistently differentiate IBD from irritable bowel syndrome because it has excellent negative predictive value in ruling out IBD in undiagnosed, symptomatic patients. Fecal calprotectin also may be useful in determining whether clinical symptoms in patients with known IBD are caused by disease flares or noninflammatory complications/underlying irritable bowel syndrome and in providing objective evidence of response to treatment. Although more studies are needed to define fully the role of fecal calprotectin, convincing studies and growing clinical experience point to an expanded role in the diagnosis and management of IBD.
I
nflammatory bowel disease (IBD), which includes Crohn_s disease (CD) and ulcerative colitis (UC), is a chronic condition marked by recurrent episodes of inflammation in the gastrointestinal tract. This inflammation underlies many of the symptoms and signs of the disease; thus, its detection and monitoring are of utmost importance in clinical management. Because gastrointestinal inflammation is not directly observable by patients or physicians, many methods have been developed to quantify the severity and extent of this inflammation.
Patient symptoms can be an important indicator of inflammation and disease activity but are subjective and may be influenced by other noninflammatory features of the disease such as intestinal strictures or bile salt malabsorption. Activity indexes such as the Crohn_s Disease Activity Index and the Harvey Bradshaw Index use a combination of symptoms, examination findings, and laboratory parameters to establish disease activity. These indexes have been rigorously developed and validated in clinical trials, 1Y3 but they are cumbersome to use in clinical practice and still rely heavily on subjective patient symptoms. Serological and hematological parameters are used widely to assess disease activity, but these systemic markers have low sensitivity and specificity for intestinal inflammation and correlate poorly with symptoms and disease activity indexes. 4, 5 Imaging studies such as CT and MRI scans, barium enemas, and enteroclysis can be useful in localizing intestinal inflammation, but these studies often are expensive, have suboptimal sensitivity and/or specificity, and may be invasive or expose the patient to ionizing radiation.
The current gold standard for assessing intestinal inflammation is endoscopy with biopsies. This technique allows visual inspection of the gastrointestinal tract, and mucosal biopsy specimens can be obtained for histological examination. The location, extent, and severity of disease can be established with this procedure, but it is invasive, cannot examine the entire gastrointestinal tract, and requires both a skilled operator and an uncomfortable preparatory regimen. Wireless capsule endoscopy has now allowed visualization of the entire small bowel. However, this is somewhat invasive and is limited by its cost and the inability to obtain tissue samples. These limitations prevent frequent assessment of disease activity by endoscopic techniques. Thus, it is clear that a simple, rapid, sensitive, specific, inexpensive, noninvasive marker to detect and monitor intestinal inflammation in IBD is needed. Fecal calprotectin may possess these characteristics.
Calprotectin is an abundant calcium-binding protein belonging to the S100 family that is derived predominantly CLINICAL REVIEW from neutrophils and, to a lesser extent, from monocytes and reactive macrophages. 6 Calprotectin constitutes $5% of the total protein and 60% of the cytosolic protein in human neutrophils. 7 It has bacteriostatic and fungistatic properties, and plasma calprotectin has been shown to increase 5-to 40-fold in infectious and inflammatory conditions. 8 Calprotectin is found in stool, and fecal calprotectin concentration is $6 times that of normal plasma. 9 Markedly elevated levels of calprotectin have been detected in the feces of patients with bowel inflammation. 10Y12 This review examines the characteristics of the fecal calprotectin assay and the evidence for its use as a noninvasive marker of inflammation.
MATERIALS AND METHODS
Recent studies published in peer-reviewed journals were identified using the search engine PubMed (http://www. 
RESULTS

Assay Characteristics
In 1992, Roseth et al 7 developed the first method for isolating and quantifying calprotectin in stool, an enzyme-linked immunosorbent assay (ELISA) using rabbit anti-calprotectin. Since then, an improved, commercially available, validated ELISA has been developed in which smaller stool samples (0.1 g) are extracted with 5 mL buffer in a closed tube. 13 This assay exhibited very good correlation (r = 0.87) compared with 3-day excretion of 111 InYlabeled granulocytes.
14 The newer assay measures calprotectin concentration in micrograms per gram rather than in milligrams per liter as in the original assay. Data obtained with the new method can be extrapolated to those of the old method through the use of a conversion factor. Calprotectin is a remarkably stable protein in the presence of calcium and is resistant to proteolytic degradation in the stool. Stool samples can be kept for up to 5 days at room temperature without appreciable loss of calprotectin, and spot samples of calprotectin in stool are as reliable as 24-h collections, with excellent correlation (r = 0.90). 7 It is recommended that 20 g stool be provided in a nonsterile container and shipped overnight to the commercial laboratory.
Several investigators have examined the intra-assay and interassay variability of both the newer and older calprotectin assays and have found them to be acceptable, with an intraassay variation of G5% and an interassay variation of 10% to 40%. 13, 15, 16 Husebye et al, 17 however, demonstrated that a subset of individuals can have labile calprotectin concentrations that have greater day-to-day variability and exceed the recommended cutoffs, thus making interpretation of a single calprotectin measurement more difficult; this may be especially true in the setting of severe diarrhea. The improved ELISA uses polyclonal antibodies that recognize 6 epitopes of calprotectin, thereby reducing falsely low results. More important, the lower level of sensitivity of the assay is such that accurate values can be obtained for individuals with both normal and inflamed mucosa, potentially allowing for sensitive noninvasive detection of mucosal healing. Receiveroperating characteristics (ROC) plot analysis has shown that a cutoff of 150 mg/g will distinguish between IBD and irritable bowel syndrome (IBS) with a sensitivity of 100% and a specificity of 97% (Fig. 1) . 15 In the United States, the assay is offered by Genova Diagnostics, with an estimated cost of $150.00. In Europe, the assay also is offered by commercial laboratories, with a somewhat lower estimated cost, or kits to run the ELISA locally may be obtained. 17 
Reference Range
Fecal calprotectin concentrations in healthy individuals have been established in several studies (Table 1 ). In the original study by Roseth et al, 7 the median stool calprotectin concentration in healthy adult controls was 2 mg/L, and the FIGURE 1. ROC analysis of the ability of calprotectin, CRP, and ESR to discriminate between patients with CD and the IBS. The solid line (''no discrimination'') indicates values that have no discriminatory value. Note that on the vertical axis, the scale is from no (0) to complete (1 or 100%) sensitivity. The horizontal axis is a reciprocal scale (1jspecificity). The optimum performance of a test is determined either as the highest sum of the specificity and sensitivity or at an acceptable level of sensitivity for the given disease. A cutoff value of 30 mg/L (150 mg/g) for fecal calprotectin gives 100% sensitivity and 97% specificity for discriminating between patients with CD and IBS. Reprinted with permission from Gut. 15 Copyright 2000, BMJ Publishing Group.
suggested cutoff for a positive test was 10 mg/L. With the newer assay, the suggested upper limit of normal has been changed to 50 mg/g. Husebye et al 17 demonstrated good correlation between the newer and older calprotectin assay when stool samples were analyzed with both methods. It has recently been shown that calprotectin concentrations increase with age in adults. 18 Reference values for healthy children also have been established, are similar to those for adults, and use the same cutoff values (Table 2) . 9 Interestingly, infants in the first year of life have been shown to have significantly higher calprotectin concentrations than healthy children or adults, with increases of >10-fold (Table 3) . 19, 20 There are conflicting data regarding the role that diet may play in the elevated calprotectin concentrations in infants. Golden et al 21 found that fecal calprotectin concentration was significantly lower in breastfed than formula-fed infants, whereas Campeotto et al 20 found no difference between these groups. Although this issue merits further study, it is important that both groups had markedly elevated fecal calprotectin concentrations compared with older children and adults.
Inflammatory Bowel Disease
Fecal calprotectin concentrations are elevated in both adults and children with IBD relative to healthy control subjects, as supported by numerous studies (Tables 4 and 5 ). Patients with IBS (a functional disorder without histologically identifiable intestinal inflammation), however, have fecal calprotectin concentrations similar to those of healthy control subjects (Table 6) . A strong positive correlation between fecal calprotectin concentration and fecal excretion of 111 In-labeled neutrophils has been found in patients with IBD, 14 supporting the hypothesis that the increase in fecal calprotectin seen in these patients is primarily a result of increased neutrophil migration into the gut lumen across inflamed mucosa. Evidence that fecal calprotectin concentrations are elevated in other conditions characterized by intestinal inflammation such as bacterial gastroenteritis 22 and nonsteroidal enteropathy 23 supports this hypothesis. Fecal calprotectin concentrations also correlate with measures of intestinal permeability ( 51 Cr-EDTA excretion, 24 lactulose/ L-rhamnose ratio 25 ), suggested as a primary defect in small bowel CD. 26 Fecal calprotectin concentration was more sensitive than small bowel barium follow-through in identifying patients with organic intestinal disease 16 and has been shown to correlate well with 99 Tc-labeled white cell scans (a sensitive indicator of inflammation) in children with IBD.
11
Fecal calprotectin concentrations correlate with endoscopic and histological assessment of disease activity in adults and children with IBD. This was originally reported by Roseth et al, 27 who showed that adults with active UC as measured by both endoscopic and histological grading systems had higher fecal calprotectin concentrations than adults with mildly active (or inactive) UC and adults with a normal colonoscopy. Bunn et al 11 replicated these results in children with IBD, showing a close correlation between fecal calprotectin concentrations and both endoscopic and histological inflammation scores. Fecal calprotectin concentrations predicted the severity of colorectal inflammation in adults, with increased fecal calprotectin concentrations strongly associated with advancing histological grades of colorectal inflammation. 28 Fecal calprotectin concentrations also have been shown to correlate with disease activity despite bowel resection surgery. Costa et al 29 examined 12 patients with CD who had undergone bowel resections; 8 of these patients had evidence of a recurrence involving the anastomosis. All 8 of these patients had elevated fecal calprotectin concentrations, whereas the 4 patients without disease recurrence had normal levels. Although there are no data on fecal calprotectin concentrations with suture line ulcers in the absence of IBD recurrence, local inflammation at the site of the ulcer could lead to elevated fecal calprotectin concentrations in the absence of active IBD, which must be considered. These studies support the conclusion that fecal calprotectin concentrations reflect neutrophilic intestinal inflammation at the tissue level.
Prediction of Relapse in IBD
The clinical course of most patients with IBD is marked by periods of remission with intermittent relapses characterized by increased intestinal inflammation. Because the timing of these relapses is unpredictable, clinical symptoms rather than invasive tests are used to monitor disease activity. Because clinical symptoms are not usually manifested early in the course of a relapse when inflammation is minimal, most IBD relapses come to medical attention after the inflammatory response has become well established. This may necessitate more intense and prolonged treatment regimens to induce remission. Because fecal calprotectin has been shown to correlate well with endoscopic and histological intestinal inflammation, its use as a predictor of relapse in patients with quiescent IBD has been examined.
Tibble et al 30 studied 43 patients with CD and 37 patients with UC in clinical remission for 1 to 4 months as determined by clinical disease activity indexes (Crohn_s Disease Activity Index and Harvey Bradshaw Index). These patients had fecal calprotectin measurements at baseline and were then followed up for 1 year. Approximately half of the patients in each group relapsed during the 12-month follow-up period as defined by specified increases in their clinical disease activity indexes. With a cutoff of 50 mg/L, the sensitivity and specificity of calprotectin for predicting relapse in all patients with IBD were 90% and 83%, respectively, with a 13-foldYincreased risk of relapse. These values were similar when patients with CD or UC were examined separately. Costa et al 31 performed a study similar in both design and number of patients to that of Tibble et al. They found nearly identical sensitivity and specificity of calprotectin for predicting relapse in UC, but their specificity of calprotectin in CD was 43%, markedly lower than the 83% reported by Tibble et al. It is unclear why this discrepancy was so large, but their study used a different assay and a lower cutoff of fecal calprotectin (150 mg/g, corresponding to 30 mg/L), which may have decreased the specificity.
When these studies are taken together, fecal calprotectin appears to be a good predictor of relapse in patients with IBD, although its value may be higher in patients with UC than in those with CD. Both studies, however, measured fecal calprotectin only at baseline and then followed up the patients for 12 months. In clinical practice, fecal calprotectin could be measured at intervals during follow-up, which may allow early detection rather than just prediction of relapses. In addition, both studies were relatively small; more studies are needed to confirm their findings and resolve the conflicting results.
Response to Treatment in IBD
Most clinicians now rely on clinical symptoms to evaluate a patient_s response to treatment because follow-up endoscopy to document improvement is invasive and cannot be performed frequently. Because fecal calprotectin concentration has been shown to correlate with endoscopic and histological inflammation in IBD, it follows that it would be a useful marker with which to follow response to treatment. Aadland and Fagerhol 32 demonstrated a transient decrease in fecal calprotectin concentrations in 2 patients with IBD after treatment with infliximab, corresponding to an improvement in clinical disease activity. These patients, however, did not undergo endoscopy with biopsies, so confirmation of histological improvement was not obtained. Roseth et al 33 documented serial fecal calprotectin concentrations in a single patient with UC over an 18-week period. Fecal calprotectin concentration decreased with treatment of UC and corresponded with clinical, endoscopic, and histological improvement. In the same study, the authors performed colonoscopies on 45 patients with IBD in clinical remission with normal fecal calprotectin concentrations. Thirty-eight of these patients had complete, histologically proven mucosal healing; the remaining 8 had evidence of only mild colonic lamina propria inflammation. Fecal calprotectin concentrations during prior active disease were available for 18 of these patients, and all were significantly elevated. Clearly, however, larger prospective studies with histological confirmation of disease activity both before and after treatment are needed to evaluate the role of fecal calprotectin in this setting.
Assessment of Ileal Pouch Inflammation
Restorative proctocolectomy is now the most common operation performed for UC. 34, 35 After this procedure, $10% to 40% of adults and children will develop clinically significant inflammation in the ileal pouch (pouchitis), 36, 37 with some estimates as high as 94% with long-term followup. 38 Accurate diagnosis of pouchitis requires endoscopy with biopsies to identify the characteristic histopathological changes of neutrophilic infiltrates, crypt abscesses, and ulceration. 39 Because of the patchy nature of the inflammation, however, the diagnosis may be unreliable. 40 Fecal calprotectin concentrations were measured in 24 adults with ileoanal pouches by Thomas et al. 41 Sixteen of these patients had UC; 8 had familial adenomatous polyposis. Nine patients showed evidence of pouch inflammation by both endoscopic and histological criteria (all had UC), and all 9 patients had elevated fecal calprotectin concentrations. Two of the 8 patients with familial adenomatous polyposis had elevated fecal calprotectin concentrations despite the absence of pouchitis, although 1 patient had a pouch anal stenosis with local inflammation requiring catheterization of the pouch. All of the other patients had normal fecal calprotectin concentrations, including all 7 of the UC patients without evidence of pouchitis. Overall, at a cutoff of 10 mg/L (50 mg/g), fecal calprotectin concentration had a sensitivity of 100% and a specificity of 87% in differentiating pouchitis from an In addition to fecal calprotectin, another neutrophil product, fecal lactoferrin, has also shown promise in the noninvasive diagnosis of pouchitis. Parsi et al 42 measured fecal lactoferrin concentrations in 60 consecutive adults with ileo-pouch anal anastomosis after total proctocolectomy for suspected UC. On the basis of symptoms, endoscopy, histological evaluation, and the Pouchitis Disease Activity Index, patients were categorized into inflammatory and noninflammatory groups. When a cutoff of 7 mg/mL was used, fecal lactoferrin was equivalent to fecal calprotectin in differentiating patients with inflammation of the pouch from normal patients or those with irritable pouch syndrome, with a sensitivity of 100% and a specificity of 85%. Because of their high sensitivities, these biomarkers can be used as screening tests to select patients for more invasive pouch endoscopy with biopsies. Although larger studies are needed, fecal calprotectin and fecal lactoferrin show promise in the noninvasive diagnosis of pouchitis.
Subclinical Intestinal Inflammation
Because of its correlation with intestinal inflammation and ease of administration, the fecal calprotectin test has been examined in apparently healthy first-degree relatives of patients with CD to assess the possible presence of subclinical intestinal inflammation in this population. In the study by Thjodleifsson et al, 43 49% of first-degree relatives of patients with CD had elevated fecal calprotectin concentrations, suggesting its use as a subclinical biomarker of IBD. In contrast, only 13% of spouses of CD patients had elevated levels, implicating genetic rather than environmental factors as the cause of the increased levels. However, because only 5% to 10% of family members of patients with CD develop clinical IBD, not all patients with subclinical intestinal inflammation will progress to clinically apparent IBD. This subset of patients with elevated fecal calprotectin concentrations deserves further study, and the use of fecal calprotectin in the detection of subclinical intestinal inflammation may help to elucidate predisposing factors to IBD.
Fecal Calprotectin Relative to Other Biomarkers
It is important to note that multiple fecal biomarkers have been evaluated with respect to screening patients for evidence of IBD. A detailed discussion of these is beyond the scope of this article. The reader is referred to a recent review by Nielsen et al 5 regarding established and emerging biomarkers for IBD, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-Saccharomyces cerevisiae antibody/perinuclear anti-neutrophil cytoplasmic antibody (ASCA/pANCA), and a variety of cytokines, chemokines, and cytokine receptors. The authors concluded that none of these assays were yet sensitive or specific enough to replace standard clinical evaluations. For example, although several studies using fecal tumor necrosis factor-a have shown promising results, large interindividual variations in both serum and fecal levels have limited its widespread applicability. Interestingly, the most promising class of fecal biomarkers for IBD to date is the neutrophil products. Lactoferrin is an iron-binding glycoprotein that is a major component of the secondary granules of neutrophils. PMNelastase is a neutral proteinase that is released by activation of neutrophils. Lysozyme also is a neutrophil-derived enzyme that mediates degradation of bacterial cell wells. Myeloperoxidase is another neutrophil product that is released from the primary granules. Data regarding direct comparisons of calprotectin with these other neutrophil products are reviewed briefly next.
Silberer et al 44 recently compared the utility of calprotectin, PMN-elastase, myeloperoxidase, lysozyme, and lactoferrin in terms of differentiating IBD from IBS. Forty subjects with IBS, 39 with chronic IBD, and 40 healthy control subjects were compared. ROC curves yielded the following areas under the curves (AUCs): PMN-elastase, 0.916; calprotectin, 0.872; myeloperoxidase, 0.750; lysozyme, 0.726; and lactoferrin, 0.693. For this analysis, the higher the ROC AUC for an assay, the greater the overall sensitivity and specificity. The AUCs for PMN-elastase and calprotectin were significantly greater than for the other assays and not different from each other. Importantly, both PMN-elastase and calprotectin also correlated well with endoscopic severity of inflammation.
In a prior study by Kane et al, 45 lactoferrin was shown to be sensitive and specific for patients with CD or UC compared with IBS patients or healthy control subjects. The sensitivity of the assay for IBD versus IBS was 78%; the specificity was 90%. The AUC for the ROC analysis was comparable to the Silberer et al study, 0.6507. The assay, approved by the US Food and Drug Administration for detecting the presence of inflammation, is currently available commercially from TechLab (Blacksburg, Va). Langhorst et al 46 compared calprotectin with lysozyme, lactoferrin, and PMN-elastase relative to a clinical index of disease activity in adults with UC. They found that 3 of these (calprotectin, r = 0.505; lactoferrin, r = 0.441; PMN-elastase, r = 0.604) were elevated in the stool in active inflammation and correlated with the degree of clinical disease activity. Of these, calprotectin had the highest sensitivity (92%) for clinically active disease, but its specificity of only 63% probably reflects ongoing subclinical mucosal inflammation. In terms of stability, after storage at room temperature for 48 hours, the fecal concentrations of calprotectin, lactoferrin, PMNelastase, and lysozyme were 82%, 90%, 80%, and 60% of the starting values. Therefore, calprotectin compares favorably with other fecal biomarkers that have been evaluated for IBD.
Combined Use of Noninvasive Tests in IBD
Recently, the utility of combining fecal calprotectin with other noninvasive tests, including serology (ASCA/ pANCA) and bowel wall ultrasound, for identifying children with IBD versus IBS has been evaluated. 47 Of 45 children examined, a diagnosis of IBD was made in 27 that was confirmed by clinical, radiographic, endoscopic, and histological criteria. The authors found that fecal calprotectin had greater sensitivity (92.6%) than ASCA/pANCA (77.8%) or bowel wall ultrasound (74.1%). Specificity of fecal calprotectin (88.9%) was comparable to that of ASCA/pANCA (88.9%) and better than that of bowel wall ultrasound (77.8%). Combining all 3 tests led to a sensitivity of 100% if 1 of the 3 was positive and a specificity of 100% if all 3 were positive. In comparison, sensitivity (66.6%) and specificity (88.8%) of using hemoglobin, ESR, and CRP in a similar manner were much lower. The odds ratio (OR) for a diagnosis of IBD with a positive value for fecal calprotectin was 68 compared with an OR of 25 for a positive result for ASCA/pANCA. Therefore, although these values were calculated from a tertiary referral population, fecal calprotectin as a single screening test provided excellent sensitivity and specificity relative to other noninvasive options.
Other Intestinal Diseases
Although fecal calprotectin has been most studied in IBD, several investigators have measured levels in patients with other intestinal diseases such as microscopic colitis, celiac disease, allergic colitis, and diverticular disease. These studies included primarily patients with IBD, however, so the numbers of patients with other intestinal diseases is small in comparison. Limburg et al 28 measured fecal calprotectin concentrations in 11 adults with microscopic colitis and found them to be higher than in patients without colorectal inflammation but lower than in those with IBD. Two other studies reported fecal calprotectin concentrations in a total of 8 patients with microscopic colitis; all 8 patients had elevated levels. 15, 48 In adult patients with active celiac disease, approximately half (12 of 22) had elevated fecal calprotectin concentrations, 25 ,48 whereas 7 of 13 children with celiac disease in one of the studies had elevated levels. 48 Berni Canani et al 22 examined a total of 38 children with both active and inactive celiac disease. They found that those patients with active celiac disease had elevated fecal calprotectin concentrations compared with healthy control subjects and that there was a trend toward normal values after 4 weeks of an exclusion diet. In the same study, 37 children with allergic colitis were examined. Similarly, those patients with active allergic colitis had elevated fecal calprotectin concentrations compared with healthy control subjects, and there was a trend toward normal values after 4 weeks of an exclusion diet. There was more overlap between those with active versus inactive allergic colitis than in the celiac disease patients, however. Elevated fecal calprotectin concentrations have been found in approximately half of a total of 52 adult patients in 4 studies with diverticular disease. 12, 15, 25, 48 Organic Versus Functional Intestinal Disease
One of the diagnostic difficulties in clinical gastroenterology is differentiating patients with histologically identifiable intestinal disease from functional disorders such as IBS that share many of the same symptoms. Although the history, physical examination, and laboratory studies often are suggestive, many patients undergo invasive intestinal endoscopy to confirm or refute a particular diagnosis. Having shown that fecal calprotectin accurately reflects intestinal inflammation in patients with known IBD, several investigators have used the fecal calprotectin assay to quantify intestinal inflammation in undiagnosed, symptomatic patients in an attempt to differentiate functional from organic disorders. In adults, 4 studies have prospectively examined undiagnosed, symptomatic patients referred to a gastroenterology clinic for evaluation. In 2 of the studies, the patients were referred to differentiate IBD from IBS 15, 25 ; patients in the other 2 studies were referred for chronic, nonbloody diarrhea. 28, 48 In children, 3 studies of this type have been performed: 2 to differentiate functional disorders from IBD 11, 47, 49 and 1 for diarrhea. 48 Test statistics for the fecal calprotectin assay in this setting are shown in Tables 7 and 8 .
IBD Versus IBS
Tibble et al 15 studied 220 consecutive adult patients with symptoms suggestive of IBD or IBS. The prevalence of organic disease in this study population was 28%. The sensitivity and specificity of fecal calprotectin (using a cutoff of 10 mg/L) in discriminating between organic and functional intestinal disease were 82% and 83%, respectively. These increased to 100% and 97% in differentiating CD from IBS when a higher cutoff (30 mg/L) was used.
In another study, the same authors measured fecal calprotectin concentrations on 602 consecutive adult referrals to the same clinic with symptoms suggestive of organic intestinal disease or IBS. 25 Patients with symptoms of isolated gastroesophageal reflux, known IBD or colorectal carcinoma, or other known serious comorbidities were excluded. All patients underwent radiological or endoscopic evaluation at the discretion of the treating gastroenterologist, were classified by Rome I criteria (clinical criteria for IBS), provided blood for routine laboratory assays, and provided a fecal sample for measurement of calprotectin. Two hundred sixty-three patients (44%) were classified as having an organic intestinal disease, and 339 patients (56%) had functional disease. The sensitivity and specificity of fecal calprotectin (using a cutoff of 10 mg/L) for organic intestinal disease were 89% and 79%, respectively, whereas for CRP (a widely used hematological marker of systemic inflammation), they were 58% and 81%. The OR for organic disease with a fecal calprotectin concentration >10 mg/L was 27.8 (95% CI, 17.6Y43.7), also higher than that for CRP (4.2; 95% CI, 2.9Y6.1). In a letter to the editor, however, DelgadoAros and Cremonini 50 pointed out that the positive likelihood ratio of organic disease based on a positive fecal calprotectin (4.2) was similar to that for the absence of Rome criteria (4.7) and did not offer additional information. A negative fecal calprotectin, however, when used in combination with presence of Rome criteria, decreased the probability of organic disease from 21% to 4% (negative likelihood ratio, 0.11) and would thus be useful for ruling out organic disease.
The 2 studies in children that used the fecal calprotectin assay to differentiate IBD from functional disorders found better positive and negative predictive values (and likelihood ratios) than those in adults, but because the studies were small, the CIs were quite large, decreasing the certainty of these conclusions ( Fig. 2 and 3 ).
Chronic Diarrhea
Limburg et al 28 studied 110 adults referred for chronic diarrhea or colitis. Colonoscopies were performed in all patients, and fecal calprotectin concentration was measured. Twenty-nine patients (26%) were found to have colorectal inflammation; 81 (74%) did not. The median fecal calprotectin concentration in the patients with colorectal inflammation was elevated >12-fold compared with those without inflammation, and the sensitivity and specificity of fecal calprotectin (using a cutoff of 100 mg/g) for histological colorectal inflammation were 83% and 90%, respectively. When only patients with IBD were considered, the sensitivity 48 also studied patients with chronic diarrhea but included both adults (n = 70) and children (n = 50). Sensitivity and specificity (64% and 80%, respectively; cutoff, 50 mg/g), as well as positive and negative predictive values (70% and 74%, respectively), in these adults were somewhat lower than in the above studies because of coexisting conditions that may elevate fecal calprotectin concentrations (nonsteroid anti-inflammatory drug use, cirrhosis) or that fecal calprotectin may not be expected to detect in all cases (celiac disease, characterized by lymphocytic infiltrates with few neutrophils). In pediatric patients, fecal calprotectin had a higher sensitivity and specificity (70% and 93%, respectively), but the positive and negative predictive values (96% and 56%, respectively) were reversed from those in the adults because of a number of cases of celiac disease with normal fecal calprotectin concentrations. Interestingly, however, Berni Canani et al 22 demonstrated an elevated fecal calprotectin concentration in children with active celiac disease compared with those with inactive disease and with healthy control subjects. Clearly, larger studies looking at fecal calprotectin concentrations in patients with celiac disease are needed.
DISCUSSION
Fecal calprotectin is a promising marker of neutrophilic intestinal inflammation. It has consistently been shown to be elevated in patients with known IBD, correlates well with histological inflammation as detected by colonoscopy with biopsies, and has been shown successfully to predict relapses and to detect pouchitis in patients with IBD. It has excellent negative predictive value in ruling out IBD in undiagnosed, symptomatic patients. Its positive predictive value in this setting is somewhat lower but still generally better than current laboratory markers of inflammation. Fecal calprotectin also appears to have better positive and negative predictive values in children than in adults, but larger studies are needed to clarify these findings. An important point, however, is that few, if any, negative studies regarding fecal calprotectin have been published. Whether this represents a potential publication bias or simply the strength of the collective data is unclear. Fecal calprotectin should not be thought of as a marker of organic disease; rather, it is a marker of neutrophilic intestinal inflammation. Many common organic intestinal diseases such as celiac disease, diverticular disease, and colorectal carcinoma are not uniformly characterized by significant neutrophilic infiltrates, and successful detection of these disorders by fecal calprotectin has been inconsistent. 48, 51, 52 Using calprotectin as a nonspecific test for all organic intestinal diseases will lead to lower sensitivity and will compromise its usefulness as a screening test. A negative fecal calprotectin test should therefore not be interpreted as a clean bill of intestinal health but rather as the absence of significant neutrophilic intestinal inflammation. This will be most helpful in differentiating patients with IBD from those with IBS and in determining whether clinical symptoms in patients with known IBD are caused by disease flares or noninflammatory complications/underlying IBS. Fecal calprotectin also may be helpful in providing objective evidence of response to FIGURE 3. Positive likelihood ratios and 95% CIs when fecal calprotectin was used to differentiate organic intestinal disease from functional disorders in both adults and children. FIGURE 2. Sensitivity and specificity of inflammatory biomarkers in screening for organic intestinal disease. Only studies that attempted to differentiate organic intestinal disease from functional disorders by enrolling symptomatic, undiagnosed patients were included. treatment in patients with IBD rather than relying solely on clinical symptoms, as is the current practice. Although more studies are needed to define fully the role of fecal calprotectin, convincing studies and growing clinical experience point to an expanded role in the diagnosis and management of IBD (Fig. 4) . Negative likelihood ratios and 95% CIs using fecal calprotectin to differentiate organic intestinal disease from functional disorders in both adults and children.
